Outcome of induction chemotherapy
| Regimen . | n . | CR/Cri, n (%) . | cMPN, n (%) . | Resistant disease, n (%) . | Induction-related death, n (%) . |
|---|---|---|---|---|---|
| First induction | |||||
| All | 38 | 14 (37) | 10 (26) | 9 (24) | 5 (13) |
| 3+7 | 25 | 8 (32) | 6 (24) | 9 (36) | 2 (8) |
| NOVE-HIDAC | 12 | 6 (50) | 4 (33) | 0 | 2 (17) |
| Acute promyelocytic leukemia induction | 1 | — | — | — | 1 (100) |
| Second induction | |||||
| NOVE- HIDAC | 6 | 4 (67) | 1 (17) | - | 1 (17) |
| Regimen . | n . | CR/Cri, n (%) . | cMPN, n (%) . | Resistant disease, n (%) . | Induction-related death, n (%) . |
|---|---|---|---|---|---|
| First induction | |||||
| All | 38 | 14 (37) | 10 (26) | 9 (24) | 5 (13) |
| 3+7 | 25 | 8 (32) | 6 (24) | 9 (36) | 2 (8) |
| NOVE-HIDAC | 12 | 6 (50) | 4 (33) | 0 | 2 (17) |
| Acute promyelocytic leukemia induction | 1 | — | — | — | 1 (100) |
| Second induction | |||||
| NOVE- HIDAC | 6 | 4 (67) | 1 (17) | - | 1 (17) |
3+7, daunorubicin and cytarabine; NOVE-HiDAC, mitoxantrone, etoposide and high-dose cytarabine.